ArticleJournal of oncology2012
Current and emerging therapeutic options in adrenocortical cancer treatment.
Article in Journal of oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 20 citations in OpenAlex.
- Ectopic Adrenocortical Cancer Originating From the Pancreas: A Case Report With Literature Review.International journal of surgical pathology · 2026Review
- Case Report: Low-dose mitotane in a case of recurrent adrenocortical carcinoma: a 20-year clinical perspective.Frontiers in oncology · 2026Article
- Adrenal Tumors in Young Adults: Case Reports and Literature Review.Medicina (Kaunas, Lithuania) · 2022Review
- Synthetic high-density lipoprotein nanoparticles: A novel therapeutic strategy for adrenocortical carcinomas.Surgery · 2016Article
- 2D-DIGE proteomic analysis identifies new potential therapeutic targets for adrenocortical carcinoma.Oncotarget · 2015Article
- Pure aldosterone-secreting adrenocortical carcinoma in a patient with refractory primary hyperaldosteronism.Endocrinology, diabetes & metabolism case reports · 2015Article
- Withanolides are potent novel targeted therapeutic agents against adrenocortical carcinomas.World journal of surgery · 2014Article
- Borderline resectable adrenal cortical carcinoma: a potential role for preoperative chemotherapy.World journal of surgery · 2014Article
- Analysis of circulating microRNAs in adrenocortical tumors.Laboratory investigation; a journal of technical methods and pathology · 2014Article
- The Role of Fascin-1 in Human Urologic Cancers: A Promising Biomarker or Therapeutic Target?Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adrenocortical carcinoma (ACC) is a very rare endocrine tumour, with variable prognosis, depending on tumour stage and time of diagnosis. The overall survival is five years from detection. Radical surgery is considered the therapy of choice in the first stages of ACC. However postoperative disease-free survival at 5 years is only around 30% and recurrence rates are frequent. o,p'DDD (ortho-, para'-, dichloro-, diphenyl-, dichloroethane, or mitotane), an adrenolytic drug with significant toxicity and unpredictable therapeutic response, is used in the treatment of ACC. Unfortunately, treatment for this aggressive cancer is still ineffective. Over the past years, the growing interest in ACC has contributed to the development of therapeutic strategies in order to contrast the neoplastic spread. In this paper we discuss the most promising therapies which can be used in this endocrine neoplasia.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.